World's Best Scientists 2026 revealed!
Bonaventura Clotet

Bonaventura Clotet

Award Badge
Immunology
Spain
2026
Award Badge
Medicine
Spain
2023

D-Index & Metrics

Immunology

D-Index
118
Citations
59316
World Ranking
351
National Ranking
3

Medicine

D-Index
118
Citations
59405
World Ranking
4018
National Ranking
55

Research.com Recognitions

  • 2026 - Research.com Immunology in Spain Leader Award
  • 2025 - Research.com Immunology in Spain Leader Award
  • 2023 - Research.com Medicine in Spain Leader Award
  • 2022 - Research.com Immunology in Spain Leader Award

Overview

Bonaventura Clotet is affiliated with IrsiCaixa in Spain and has a substantial record of research contributions primarily in the field of Medicine. Their work extensively covers infectious diseases, virology, molecular biology, immunology, and epidemiology. The scientist's publication count in these subfields includes 252 papers on Infectious Diseases, 59 on Virology, 41 on Molecular Biology, 41 on Immunology, and 40 on Epidemiology.

The main topics investigated by Clotet encompass a range of areas related to viral infections and their clinical aspects, including:

  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • HIV Research and Treatment
  • SARS-CoV-2 detection and testing
  • HIV/AIDS Research and Interventions
  • HIV/AIDS drug development and treatment
  • Long-Term Effects of COVID-19

Their recent publications include:

  • "Mpox in people with advanced HIV infection: a global case series" (2023), published in The Lancet
  • "Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study" (2021), published in The Lancet Infectious Diseases
  • "Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial" (2020), published in Clinical Infectious Diseases
  • "Use of antiviral drugs to reduce COVID-19 transmission" (2020), published in The Lancet Global Health
  • "A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19" (2020), published in New England Journal of Medicine

Clotet frequently collaborates with several co-authors, including:

  • Julià Blanco
  • Jorge Carrillo
  • Nuria Izquierdo-Useros
  • Roger Paredes
  • Benjamin Trinité

The scientist has also published extensively in certain prominent venues, such as:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Scientific Reports
  • Frontiers in Immunology
  • Viruses
  • Journal of Antimicrobial Chemotherapy

Best Publications

  • Update of the Drug Resistance Mutations in HIV-1.

    Victoria A Johnson;Francoise Brun-Vezinet;Bonaventura Clotet;Huldrych F Gunthard

  • Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy

    Alison J. Rodger;Valentina Cambiano;Tina Bruun;Pietro Vernazza

  • Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

    Roy M. Gulick;Jacob Lalezari;James Goodrich;Nathan Clumeck

  • Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

    Roy T. Steigbigel;David A. Cooper;Princy N. Kumar;Joseph E. Eron

  • Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

    Adriano Lazzarin;Bonaventura Clotet;David Cooper;Jacques Reynes

  • Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an international AIDS society-USA panel

    Martin S. Hirsch;Françoise Brun-Vézinet;Richard T. D'Aquila;Scott M. Hammer

  • Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management

    M S Hirsch;B Conway;R T D'Aquila;V A Johnson

  • Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.

    Adriano Lazzarin;Thomas Campbell;Bonaventura Clotet;Margaret Johnson

  • Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

    Martin S. Hirsch;Françoise Brun-Vézinet;Bonaventura Clotet;Brian Conway

  • Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

    Bonaventura Clotet;Nicholas Bellos;Jean Michel Molina;David Cooper

  • Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel

    Martin S. Hirsch;Huldrych F. Günthard;Jonathan M. Schapiro;Francoise Brun-Vezinet

  • HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects

    Maria J Buzón;Marta Massanella;Josep M Llibre;Anna Esteve

  • Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

    Bonaventura Clotet;Judith Feinberg;Jan Van Lunzen;Marie Aude Khuong-Josses

  • Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

    David A. Cooper;Roy T. Steigbigel;Jose M. Gatell;Jurgen K. Rockstroh

  • Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths.

    Paul Bastard;Adrian Gervais;Adrian Gervais;Tom Le Voyer;Tom Le Voyer;Jérémie Rosain;Jérémie Rosain

  • Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

    David A. Margolis;Juan Gonzalez-Garcia;Hans Jürgen Stellbrink;Joseph J. Eron

  • Update of the Drug Resistance Mutations in HIV-1: 2005.

    Victoria A. Johnson;Françoise Brun-Vézinet;Bonaventura Clotet;Brian Conway

  • Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study

    Linda Wittkop;Huldrych F Günthard;Frank de Wolf;David Dunn

  • Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

    Calvin J Cohen;Jaime Andrade-Villanueva;Bonaventura Clotet;Jan Fourie

  • Gut Microbiota Linked to Sexual Preference and HIV Infection.

    Marc Noguera-Julian;Marc Noguera-Julian;Muntsa Rocafort;Yolanda Guillén;Javier Rivera

  • Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials

    Charles B Hicks;Pedro Cahn;David A Cooper;Sharon L Walmsley

Frequent Co-Authors

Lidia Ruiz
Lidia Ruiz IrsiCaixa
Eugenia Negredo
Eugenia Negredo University of Vic - Central University of Catalonia
Julià Blanco
Julià Blanco IrsiCaixa
Javier Martinez-Picado
Javier Martinez-Picado University of Vic - Central University of Catalonia
Roger Paredes
Roger Paredes University of Vic - Central University of Catalonia
José A. Esté
José A. Esté Autonomous University of Barcelona
José M. Gatell
José M. Gatell University of Barcelona
Vincent Soriano
Vincent Soriano Universidad Internacional De La Rioja
Miguel Angel Martínez
Miguel Angel Martínez Autonomous University of Barcelona
Pere Domingo
Pere Domingo Autonomous University of Barcelona

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open diverse career opportunities. Nursing programs, especially accelerated pathways, provide a strong foundation in patient care, which complements knowledge in immunological sciences.

Many students find that programs like accelerated FNP offer a rapid route to becoming family nurse practitioners, integrating clinical skills with immunology expertise. For non-nurses looking to enter the field, online accelerated nursing programs for non nurses provide accessible pathways to obtain essential nursing credentials without prior experience.

When choosing nursing programs, some prefer easier admissions as a starting point. Options like the easiest ABSN to get into can make the transition smoother, helping students quickly gain a Bachelor of Science in Nursing. Similarly, exploring easy admission LPN programs can be a practical pathway for those aiming to enter the healthcare workforce with licensed practical nurse credentials, complementing immunology-focused roles.

These diverse online degree options enable students and professionals to tailor their education towards impactful careers in healthcare and immunology research, fostering both clinical and scientific expertise.

Best Scientists Citing Bonaventura Clotet

Trending Scientists